Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) Short Interest Up 240.6% in March

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) was the recipient of a significant increase in short interest in the month of March. As of March 13th, there was short interest totaling 419,845 shares, an increase of 240.6% from the February 26th total of 123,268 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily volume of 668,569 shares, the short-interest ratio is presently 0.6 days.

Daiichi Sankyo Price Performance

Shares of DSNKY stock traded down $0.83 during trading hours on Thursday, hitting $17.87. The company had a trading volume of 205,960 shares, compared to its average volume of 534,275. Daiichi Sankyo has a 12 month low of $17.44 and a 12 month high of $28.21. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.85 and a current ratio of 2.69. The firm’s fifty day moving average is $19.00 and its 200 day moving average is $21.94. The firm has a market capitalization of $33.85 billion, a price-to-earnings ratio of 16.39, a PEG ratio of 1.15 and a beta of -0.35.

Daiichi Sankyo (OTCMKTS:DSNKY) last posted its earnings results on Thursday, January 29th. The company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.25 by $0.05. Daiichi Sankyo had a return on equity of 18.64% and a net margin of 14.83%.The business had revenue of $3.65 billion during the quarter, compared to the consensus estimate of $3.88 billion. On average, sell-side analysts predict that Daiichi Sankyo will post 0.73 EPS for the current fiscal year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.